XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

XenTech exhibits at AACR digital-Annual Meeting 2021

10+ New cellular models derived from our low-passage PDX panel (for a total of 40+ models available by now) Several newly added Breast cancer PDX (for a total of 50+ models) highly characterized for DDR -related projects New models in our Match-R PDX line (resistant models to latest targeted therapies) New additions to our outstanding […]


Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....


Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...